[A25-42 ] Mirikizumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V
Last updated 16.06.2025
Project no.:
A25-42
Commission:
Commission awarded on 10.03.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- Patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or were intolerant to a biologic agent (TNFα antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-42
| Project no. | Title | Status |
|---|---|---|
| A23-73 | Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V | Commission completed |